Quininib

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 527024

CAS#: 143816-42-6

Description: Quininib is a novel Regulator of Ocular Angiogenesis, significantly inhibiting angiogenic tubule formation in HMEC-1 cells, angiogenic sprouting in aortic ring explants and retinal revascularisation in OIR mice.

Chemical Structure

Quininib

CAS# 143816-42-6

Instruction

Theoretical Analysis

MedKoo Cat#: 527024
Name: Quininib
CAS#: 143816-42-6
Chemical Formula: C17H13NO
Exact Mass: 247.10
Molecular Weight: 247.297
Elemental Analysis: C, 82.57; H, 5.30; N, 5.66; O, 6.47

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 240
25mg	USD 600
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Quininib

IUPAC/Chemical Name: 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol

InChi Key: NXNDEWNGCMCWMA-ZRDIBKRKSA-N

InChi Code: InChI=1S/C17H13NO/c19-17-8-4-2-6-14(17)10-12-15-11-9-13-5-1-3-7-16(13)18-15/h1-12,19H/b12-10+

SMILES Code: OC1=CC=CC=C1/C=C/C2=NC3=CC=CC=C3C=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 247.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Butler CT, Reynolds AL, Tosetto M, Dillon ET, Guiry PJ, Cagney G, O'Sullivan J, Kennedy BN. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab. J Biol Chem. 2017 Mar 3;292(9):3552-3567. doi: 10.1074/jbc.M116.747766. Epub 2016 Dec 29. PubMed PMID: 28035003; PubMed Central PMCID: PMC5339742.

2: Murphy AG, Casey R, Maguire A, Tosetto M, Butler CT, Conroy E, Reynolds AL, Sheahan K, O'Donoghue D, Gallagher WM, Fennelly D, Kennedy BN, O'Sullivan J. Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer. Sci Rep. 2016 Oct 14;6:34523. doi: 10.1038/srep34523. PubMed PMID: 27739445; PubMed Central PMCID: PMC5064353.

3: Galvin O, Srivastava A, Carroll O, Kulkarni R, Dykes S, Vickers S, Dickinson K, Reynolds AL, Kilty C, Redmond G, Jones R, Cheetham S, Pandit A, Kennedy BN. A sustained release formulation of novel quininib-hyaluronan microneedles inhibits angiogenesis and retinal vascular permeability in vivo. J Control Release. 2016 Jul 10;233:198-207. doi: 10.1016/j.jconrel.2016.04.004. Epub 2016 Apr 13. PubMed PMID: 27086168.

4: Reynolds AL, Alvarez Y, Sasore T, Waghorne N, Butler CT, Kilty C, Smith AJ, McVicar C, Wong VH, Galvin O, Merrigan S, Osman J, Grebnev G, Sjölander A, Stitt AW, Kennedy BN. Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis. J Biol Chem. 2016 Apr 1;291(14):7242-55. doi: 10.1074/jbc.M115.710665. Epub 2016 Feb 4. PubMed PMID: 26846851; PubMed Central PMCID: PMC4817159.

Your view history